Immupharma Share Discussion Threads

[nobbygnome] 31/8/2018 09:15

LOL

I looked at the details of the trial ages ago.

And it is entirely logical because the argument would be that Lupus is really multiple diseases and the anti DNA antibodies identifies the patients with true Lupus.

[brad44] 31/8/2018 09:07

lol well spotted francis. nobby is so far up himself he will disappear..

[francisgalton] 31/8/2018 09:00

For nobbygnome

No you are wrong yet again. Anifrolumab did not use the same biomarker as a requirement in their trial. You read this from another poster and have copied them since without even checking whether they were right or not [cardinal research sin I add].

Anifrolumab had no requirement for anti-dsDNA antibodies. It was optional - patients only had to have at screening either a positive ANA test by IFA OR a elevated anti-dsDNA antibodies OR elevated Anti-Smith (anti-Sm) antibodies at screening. Therefore they were not just testing patients with elevated anti-dsDNA antibodies.

Your research is just plain lazy.

In any event, even if anifrolumab were testing just anti-dsDNA patients, that proves nothing in relation to Lupuzor. They have different measures of action. Your point is illogical.

[brad44] 31/8/2018 08:56

ken chung promoting opti, daft fxxxer was slagging opti off 2 weeks ago, saying it was a wifestyle company. maybe he is one of those reverse indicators. a sort of fortune cookie..

[john202] 31/8/2018 08:56

What £1000 Profit?What was the initial investment?Curious.

[stockriser] 31/8/2018 08:56

NG - "So there is nowhere to go now....." - So that's it then Nobby, is there absolutely nothing else IMM might have up their sleeve?

I mean they have enough money for approx. the next 4yrs, surely there is something, don't leave me in despair .....lol ;-)

[nobbygnome] 31/8/2018 08:48

LOL Strangely all humans are fallible. However, I got MTPH right and pocketed a four figure sum this morning!

This is actually very bad news for IMM. This trial used the anti DNA antibody biomarker which IMM were trying to trumpet in their post hoc analysis. So there is nowhere to go now.....

Just shows how difficult a disease Lupus is which adds to the argument they should move on to a different disease with a proper dose!

Nobby

[francisgalton] 31/8/2018 08:38

The anifrolumab Phase III failure announced today is massive news for Immupharma. Buys us the time we need to get our second Phase 3 trial through on the anti-dsDNA patients and to be next on the market. The news is huge for IMM.

For nobbygnome and for those who think he is credible or infallible, perhaps you can come on here and admit you got it massively wrong on anifrolumab. I recall nobbygnome endlessly ramping anifrolumab on here saying things on here this year like:

"Anifrolumab on the other hand I expect to produce good results very soon."

"If you are talking about Lupus, anifrolumab will produce a positive phase III result IMHO; the result is due shortly."

"I predict that anifrolumab will have a positive phase III result"

"Anifrolumab would be my preferred treatment if I had to take something off label."

"Anifrolumab stands a good chance of getting close to significance because it really does work IMHO"

[stockriser] 31/8/2018 08:32

NG - you're the pharma man, what's your thoughts on the results of anifrolumab, and could this affect IMM in any way? Has the market been awaiting these results?

TIA SR

[a0148009] 31/8/2018 08:14

By Oliver Griffin


AstraZeneca PLC (AZN.LN) and MedImmune, its global biologics research and development business, said Friday that a phase 3 trial for anifrolumab, which targets systemic lupus erythematosus, didn't meet its primary goal.

The pharmaceutical company said top-line results from the first treatment of uncontrolled lupus via the interferon pathway, or Tulip, phase 3 trial didn't meet its primary endpoint of a statistically significant reduction in disease activity in patients with systemic lupus erythematosus.

Systemic lupus erythematosus is an autoimmune disease where the immune system attacks healthy tissue in the body, instead of first targeting viruses or other foreign invaders. It can cause a range of symptoms including pain, fevers and swollen joints.

"The result of this trial is disappointing for patients and the lupus community," said Sean Bohen, AstraZeneca's executive vice president of global medicines development and its chief medical officer.

The company said that a full evaluation of the data will be conducted when data from the second Tulip phase 3 trial is available later in the year.

[francisgalton] 28/8/2018 23:43

Evening money maker

[money maker1] 28/8/2018 23:33

Evening all!!

[nobbygnome] 28/8/2018 21:47

PS SUMM have got more cash too...

[nobbygnome] 28/8/2018 21:46

Compare the market cap with SUMM. A very similar situation in that the lead drug failed.....but SUMM have another drug in phase III. Meanwhile IMM have nothing anywhere near trials let alone in phase III. I wonder which has the higher market cap....

[kirk 6] 28/8/2018 21:36

Hope you are right here in with nearly 1m here now. Big support at 20p big upside hereMy target here is 30-35p short term

[dopey47] 28/8/2018 21:33

And we have an update coming shortly on CIDP. This share is so undervalued and IMM is not a one trick pony. You can feel the momentum developing in the shares over the past couple of weeks.

[tarny] 28/8/2018 21:26

We are nearly there now bargainbob, it's been well worth the wait :)

IMHO, DYOR etc etc

[bargainbob] 28/8/2018 21:06

Are we there yet.

[tarny] 28/8/2018 21:02

By going LONG actually...I think even you will be very pleasantly surprised LOL :)

DYOR

[nobbygnome] 28/8/2018 20:49

PS I expect a gerrymandered RNS shortly saying everything is going swimmingly.....but no deal yet!

[nobbygnome] 28/8/2018 20:47

LOL yes by shorters......

I am not one BTW.